Abstract |
The aim of the present study was to evaluate an intensive chemotherapy regimen in patients with diffuse large B-cell lymphoma and poor prognosis, as presence of high- or high-intermediate clinical risk, bulky disease, high levels of beta 2 microgloblin, and more than two extranodal sites of involvement at diagnosis. One hundred previously untreated patients were treated with an intensive CEOP-Bleo regimen with increased doses of cyclophosphamide (1000 mg/m(2)) and epirubicin (120 mg/m(2)) in each cycle. Granulocyte colony-stimulating factors was employed to ameliorate severe granulocytopenia. Complete response was achieved in 79 cases (79%). With a median follow-up of 32.3 mo (range 10-45 mo) only seven patients have relapsed. Thus, actuarial curves at 3 yr, showed that event-free survival was 72%. Five died secondary to tumor progression, actuarial curves at 3-yr for overall survival were 75%. Toxicity was mild, granulocytopenia grade III or IV were observed in the 46% of the cycles; infection-related granulocytopenia was observed in 17%, but no fatality due to therapy was observed. Cardiac toxicity was mild, only seven patients showed a drop in left ejection ventricular function, but no symptomatic heart failure has been observed. The intensive CEOP-Bleo regimen with increasing doses of cyclophosphamide and epirubicin is a useful and well-tolerated regimen in the treatment of poor prognosis diffuse large B-cell lymphoma.
|
Authors | Agustin Avilés, M Jesús Nambo, Natividad Neri, Alejandra Talavera, Claudia Castañeda, Edgar Murillo, Sergio Cleto, Judith Huerta-Guzmán |
Journal | Medical oncology (Northwood, London, England)
(Med Oncol)
Vol. 21
Issue 3
Pg. 269-72
( 2004)
ISSN: 1357-0560 [Print] United States |
PMID | 15456955
(Publication Type: Clinical Trial, Comparative Study, Journal Article)
|
Chemical References |
- Antibiotics, Antineoplastic
- Antimetabolites, Antineoplastic
- Antineoplastic Agents, Alkylating
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Phytogenic
- Bleomycin
- Epirubicin
- Vincristine
- Doxorubicin
- Cyclophosphamide
- Prednisone
|
Topics |
- Adult
- Aged
- Antibiotics, Antineoplastic
(administration & dosage)
- Antimetabolites, Antineoplastic
(administration & dosage)
- Antineoplastic Agents, Alkylating
(administration & dosage)
- Antineoplastic Agents, Hormonal
(administration & dosage)
- Antineoplastic Agents, Phytogenic
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Bleomycin
(administration & dosage)
- Cyclophosphamide
(administration & dosage, therapeutic use)
- Doxorubicin
(administration & dosage, therapeutic use)
- Epirubicin
(administration & dosage)
- Female
- Follow-Up Studies
- Humans
- Lymphoma, B-Cell
(drug therapy, mortality)
- Male
- Middle Aged
- Prednisone
(administration & dosage, therapeutic use)
- Prognosis
- Risk Factors
- Survival Analysis
- Time Factors
- Treatment Outcome
- Vincristine
(administration & dosage, therapeutic use)
|